Compare STRO & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRO | CBAT |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 79.2M |
| IPO Year | 2018 | N/A |
| Metric | STRO | CBAT |
|---|---|---|
| Price | $16.60 | $0.82 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $18.88 | N/A |
| AVG Volume (30 Days) | 131.7K | ★ 149.1K |
| Earning Date | 03-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $105,646,000.00 | ★ $161,757,685.00 |
| Revenue This Year | $63.08 | $16.06 |
| Revenue Next Year | N/A | $70.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.23 | $0.57 |
| 52 Week High | $21.25 | $1.25 |
| Indicator | STRO | CBAT |
|---|---|---|
| Relative Strength Index (RSI) | 74.44 | 39.18 |
| Support Level | $14.08 | $0.82 |
| Resistance Level | $17.33 | $0.86 |
| Average True Range (ATR) | 1.47 | 0.03 |
| MACD | 0.17 | -0.00 |
| Stochastic Oscillator | 89.28 | 18.71 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.